Please wait while the formulary information is being retrieved.
DAPTACEL DTAP (DIPHTHERIA, PERTUSSIS(ACELL), TETANUS PED VACC/PF)
- Diphtheria-pertussis-tetanus combined prevention
Daptacel (DTaP Pediatric) (PF) 15 Lf unit-10 mcg-5 Lf/0.5 mL IM susp
- Dosage information is not available
- None
Contraindicated
- fingolimod
- Gilenya
Severe
Moderate
- None
- None
Contraindicated
- Coma
- Guillain-barre syndrome
- Uncontrolled epilepsy
Severe
Moderate
- None
DAPTACEL DTAP (DIPHTHERIA, PERTUSSIS(ACELL), TETANUS PED VACC/PF)
- Diphtheria-pertussis-tetanus combined prevention
- None
- Anorexia
- Fatigue
- Headache disorder
- Injection site sequelae
- Myalgias
More Frequent
Severe
Less Severe
- None
- Acute abdominal pain
- Arthralgias
- Chills
- Diarrhea
- Lymphadenopathy
- Nausea
- Skin rash
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abscess
- Anaphylaxis
- Angioedema
- Apnea
- Brachial plexus disorder
- Cyanosis
- Encephalitis
- Encephalopathy
- Extensive limb swelling after injection
- Guillain-barre syndrome
- High fever >101 degrees fahrenheit
- Hypersensitivity drug reaction
- Hypotension
- Myelitis
- Myocarditis
- Myositis
- Seizure disorder
- Syncope
- Thrombocytopenic disorder
- Tonic clonic seizure
- Urticaria
Less Severe
- Back pain
- Bronchitis
- Bruising
- Cellulitis
- Cough
- Drowsy
- Earache
- Edema
- Erythema
- Facial palsy
- Fever
- Hypesthesia
- Induration of skin
- Muscle spasm
- Paresthesia
- Pruritus of skin
- Upper respiratory infection
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Diphth,Pertussis(Acel),Tet (DTaP)
Safety and efficacy not established for infants less than 6 weeks old.
DTaP not recommended. Use Tdap for booster or immunization lapse.
Risk of apnea in infants born prematurely.
- 1 Day – 41 Days
- Safety and efficacy not established for infants less than 6 weeks old.
- 8 Years – 18 Years
- Safety and efficacy not established for infants less than 6 weeks old.
- 42 Days – 364 Days
- Safety and efficacy not established for infants less than 6 weeks old.
Diphth,Pertussis(Acel),Tet (DTaP)
Safety and efficacy not established for infants less than 6 weeks old.
DTaP not recommended. Use Tdap for booster or immunization lapse.
Risk of apnea in infants born prematurely.
- 1 Day – 41 Days
- DTaP not recommended. Use Tdap for booster or immunization lapse.
- 8 Years – 18 Years
- DTaP not recommended. Use Tdap for booster or immunization lapse.
- 42 Days – 364 Days
- DTaP not recommended. Use Tdap for booster or immunization lapse.
Diphth,Pertussis(Acel),Tet Ped
Safety and efficacy not established for infants less than 6 weeks old.
DTaP not recommended. Use Tdap for booster or immunization lapse.
Risk of apnea in infants born prematurely.
- 1 Day – 41 Days
- Risk of apnea in infants born prematurely.
- 8 Years – 18 Years
- Risk of apnea in infants born prematurely.
- 42 Days – 364 Days
- Risk of apnea in infants born prematurely.
Diphtheria,pertussis(acel),tetanus
- Severity Level:
B
- Additional Notes: Cdc recommends tdap for pregnant women, and for each pregnancy
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Diphtheria,pertuss,tetanus Vaccine
Cdc recommends tdap for women who plan to breastfeed
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Unknown | No adverse effect | Cdc recommends tdap for women who plan to breastfeed |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Diphtheria-pertussis-tetanus combined prevention | |
| Z23 | Encounter for immunization |
| 0-9 | A-Z |
|---|---|
| Z23 | Encounter for immunization |
Formulary Reference Tool